Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

NCT01980875 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Idelalisib
DRUG: Chlorambucil
DRUG: Obinutuzumab

Sponsor

Gilead Sciences